122 related articles for article (PubMed ID: 37788788)
1. Tumor differentiation impacts response to neoadjuvant therapy and survival in patients with esophageal adenocarcinoma.
McKay SC; Louie BE; Molena D; Andrews WG; Boerner T; Hofstetter WL; Yeung J; Darling GE; Sharata A; Peyre CG; Dunn C; Lipham JC; Marginean H; DeMeester SR
J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1943-1950. PubMed ID: 37788788
[TBL] [Abstract][Full Text] [Related]
2. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
3. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
7. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
8. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.
Corsini EM; Foo WC; Mitchell KG; Zhou N; Maru DM; Ajani JA; Hofstetter WL; ; Correa AM; Antonoff MB; Lin SH; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL
J Thorac Cardiovasc Surg; 2021 Nov; 162(5):1404-1412.e2. PubMed ID: 33010880
[TBL] [Abstract][Full Text] [Related]
9. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
[TBL] [Abstract][Full Text] [Related]
11. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).
Yoon HH; Ou FS; Soori GS; Shi Q; Wigle DA; Sticca RP; Miller RC; Leenstra JL; Peller PJ; Ginos B; Heying E; Wu TT; Drevyanko TF; Ko S; Mattar BI; Nikcevich DA; Behrens RJ; Khalil MF; Kim GP; Alberts SR
Eur J Cancer; 2021 Jun; 150():214-223. PubMed ID: 33934058
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
14. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
[TBL] [Abstract][Full Text] [Related]
16. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
[TBL] [Abstract][Full Text] [Related]
17. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
19. Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy.
Patel AK; Pan X; Vila DM; Frankel WL; Chen W; Perry KA; Merritt RE; D'Souza DM; Wuthrick EJ; Williams TM
J Clin Pathol; 2021 Apr; 74(4):228-233. PubMed ID: 32317290
[TBL] [Abstract][Full Text] [Related]
20. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.
Donahue JM; Nichols FC; Li Z; Schomas DA; Allen MS; Cassivi SD; Jatoi A; Miller RC; Wigle DA; Shen KR; Deschamps C
Ann Thorac Surg; 2009 Feb; 87(2):392-8; discussion 398-9. PubMed ID: 19161745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
